Skip to content

Assessing Motor Neuron Disease Mechanisms by Threshold Tracking Transcranial Magnetic Stimulation and Magnetic Resonance Spectroscopy

Assessing Motor Neuron Disease Pathophysiology by Two Novel Methods - Threshold Tracking Transcranial Magnetic Stimulation and Magnetic Resonance Spectroscopy

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03664206
Enrollment
0
Registered
2018-09-10
Start date
2018-02-16
Completion date
2024-02-01
Last updated
2024-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis, Cortical Excitability, Motor Neuron Disease

Keywords

Treshold Tracking Transcranial Magnetic Stimulation, Magnetic Resonance Spectroscopy, Inter-rater agreement, Reproducibililty of Results, Case-control Studies, Biomarkers, Intra-rater agreement

Brief summary

Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which cases the death of neurons controlling the voluntary muscles. The death of motor neurons leads eventually to muscle weakness and muscle atrophy and as a consequence thereof, ALS patients die in average within three years after symptom onset due to respiratory failure. No cure for ALS is currently known, and the medical diagnosis and clinical treatment are impeded by the lack of reliable diagnostic tools for objective disease assessment, and by the limited insight in disease pathophysiology since the underlying disease mechanisms still have not been fully elucidated. An unbalance in the concentrations of GABA and glutamate, the most important inhibitory and excitatory brain metabolites, is suggested to play a role in the disease mechanisms of ALS. By applying Magnetic Resonance Spectroscopy (MRS), a magnetic resonance method which allows for quantification of brain metabolites, GABA and glutamate concentration can be quantified and thus hopefully elucidate their role in ALS disease mechanism. Threshold Tracking Transcranial Magnetic Stimulation (TT-TMS) studies carried out by a single research group have demonstrated cortical hyperexcitability (a physiology state in which neurons in the cerebral cortex are easier activated) as an early feature in ALS patients. For this reason, TT-TMS was suggested as a biomarker of ALS by the research group. However, to be able to suggest a test as a biomarker, one must show the test is reliable and reproducible. The objectives of this study are therefore: to explore the pathophysiology of ALS by investigating the interaction between neuronal networks as assessed by TT-TMS and conventional TMS and MRS, and to investigate the reliability and reproducibility of TT-TMS. The aim is to examine the utility of TT-TMS and MRS as diagnostic tools for objective detection of ALS in the early disease stage. The study will include 60 participants in total, subdivided into two groups: 30 healthy participants and 30 patients with clinical suspicion of motor neuron disease or ALS. Each participant will undergo examination with TMS and MRS, the primary outcomes will be compared between the two groups and the results from the TMS examinations and the MRS-scans will be correlated.

Interventions

DIAGNOSTIC_TESTMRS, conventional TMS and treshold tracking TMS

Using * two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil * SPECIAL MR Spectroscopy sequence In addition, each group will undergo neurological examination

Sponsors

Lundbeck Foundation
CollaboratorOTHER
Aage og Johanne Louis-Hansens Fond
CollaboratorOTHER
The A.P Moeller Foundation for Advancement of Medical Science
CollaboratorUNKNOWN
Danish Council for Independent Research
CollaboratorOTHER
Aarhus University Hospital
CollaboratorOTHER
Central Denmark Region
CollaboratorOTHER
Sándor Beniczky
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Patients with * possible, probable or definite ALS according to international criteria; * progressive muscular atrophy; * clinical suspicion of motor neuron disease or ALS Healthy participants: no younger than 45 years of age

Exclusion criteria

Patients and healthy participants: * ealier central or peripheral nervous system disease * pacemaker or other implants * pregnancy * use of medications known to affect central nervous system

Design outcomes

Primary

MeasureTime frameDescription
short interval intracortical inhibition (SICI) measured by threshold tracking TMS8 hoursMeasurement of the relative change in resting motor threshold during different interstimulus intervals and stimulus intensities
short interval intracortical inihibition (SICI) measured by conventional TMS8 hoursMeasurement of the size of motor evoked potentials (MEP) during different interstimulus intervals and a predetermined stimulus intensity
Concentration of GABA and glutamate1 hourConcentration of GABA and glutamate quantified as a ratio of creatine or tissue water content

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026